首页> 外文OA文献 >Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

【2h】

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

机译：Raltegravir结合优化的背景疗法在有治疗经验的耐药HIV感染患者中的长期疗效和安全性：BENCHMRK 1和2期III期试验的第96周结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
STEIGBIGEL RT; COOPER DA; TEPPLER H; ERON JJ; GATELL JM; KUMAR PN; ROCKSTROH JK; SCHECHTER M; KATLAMA C; MARKOWITZ M; YENI P; LOUTFY MR; LAZZARIN A; V. VULLO; LENNOX JL; CLOTET B; ZHAO J; WAN H; RHODES RR; STROHMAIER KM; BARNARD RJ; ISAACS RD; NGUYEN BY; BENCHMRK STUDY TEAMSA;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
专利

1. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials. [J] . Steigbigel RT, Cooper DA, Teppler Clinical infectious diseases . 2010,第4期

机译：Raltegravir结合优化的背景疗法在有治疗经验的耐药HIV感染患者中的长期疗效和安全性：BENCHMRK 1和2期iii期试验的第96周结果。
2. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patientsn with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials [J] . Clinical Infectious Diseases . 2010,第4期

机译：Raltegravir的长期疗效和安全性与优化的背景治疗方法相结合，可用于治疗经验丰富的耐药性HIV感染患者：BENCHMRK 1和2期III期试验第96周的结果
3. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300. [J] . Hull MW, Montaner JS Expert opinion on pharmacotherapy . 2010,第8期

机译：依那韦与达那那韦/利托那韦联合使用以及优化的背景治疗方案可抑制有治疗经验的患者的HIV复制。 Katlama C，Haubrich R，Lalezari J等的评估。依曲韦林在治疗经验丰富的HIV-1患者中的疗效和安全性：两项随机对照试验的48周汇总分析。艾滋病2009; 23：2289-300。
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials [O] . Roy T. Steigbigel, David A. Cooper, Hedy Teppler, -1

机译：Raltegravir的长期疗效和安全性与优化的背景疗法相结合在具有治疗抗药性的HIV感染患者中进行治疗：BENCHMRK 1和2期III期试验第96周的结果
6. Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2 [O] . W David Hardy, Roy M Gulick, Howard Mayer, 2010

机译：Maraviroc在治疗中的两年安全性和病毒学疗效 - 经验丰富的CCR5-Tropic HIV-1感染患者：96周的综合分析促进1和2

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

著录项

相似文献

相关主题

期刊订阅